ALDX - CIK 0001341235
The table below shows Aldeyra Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $25.66M | $48.22M | $29.46M | $47.31M | $44.94M | $24.68M |
| SG&A | $9.60M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $11.89M |
| $13.34M |
| $15.37M |
| $11.28M |
| $9.99M |
| Operating income | -$35.27M | -$60.12M | -$42.79M | -$62.68M | -$56.22M | -$36.42M |
| Income tax | $0.00 | $1.00K | $0.00 | $0.00 | $0.00 | -$479.26K |
| Net income | -$33.85M | -$55.85M | -$37.54M | -$62.02M | -$57.78M | -$37.55M |
| EPS (diluted) | -$0.56 | -$0.94 | -$0.64 | -$1.06 | -$1.07 | - |